Synaptogenix

Synaptogenix, Inc. is a biopharmaceutical company, which engages in the development of Bryostatin and Platform Drug used for the treatment of Alzheimer’s disease, Fragile X Syndrome or Autism, Multiple Sclerosis, Parkinson’s Disease, Traumatic Brain Injury, and Stroke. The company was founded on October 31, 2012 and is headquartered in New York, NY.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Synaptogenix, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the development of Bryostatin and Platform Drug used for the treatment of Alzheimer’s disease, Fragile X Syndrome or Autism, Multiple Sclerosis, Parkinson’s Disease, Traumatic Brain Injury, and Stroke. The company was founded on October 31, 2012 and is headquartered in New York, NY.

NEW YORK, June 7, 2021 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today issued a statement following the announced FDA approval of Biogen's new Alzheimer's treatment Aducanumab. Daniel Alkon, M.D.

Synaptogenix Responds to FDA Approval of Aducanumab

NEW YORK, June 7, 2021 /PRNewswire/ -- Synaptogenix, Inc. (OTC: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, announced today that it has been approved to uplist to The Nasdaq Capital Market ("Nasdaq"). Trading on the Nasdaq is expected to begin effective today at the open of the market, June 7th, 2021 under the Company's ticker symbol "SNPX.

Synaptogenix Announces Approval for Nasdaq Stock Market Listing

NEW YORK, May 19, 2021 /PRNewswire/ -- Synaptogenix, Inc. (OTC: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, announced that the Company's Board of Directors has approved a one-for-four reverse stock split of its common stock effective prior to the opening of the market today, Wednesday, May 19, 2021. The Board of Directors of Synaptogenix determined this reverse stock split to be necessary in order for the Company to fulfill the stock price requirements for official listing on the Nasdaq Stock Market.

Synaptogenix Announces Plan to Uplist on the Nasdaq Stock Market

NEW YORK, April 26, 2021 /PRNewswire/ -- Synaptogenix, Inc. (OTC: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that Dr. Daniel Alkon, the Company's President and Chief Scientific Officer, will present a "Spotlight Showcase" of Synaptogenix under the title "Regenerative Therapeutics" on Wednesday, April 28 th at 12:40pm ET. "Synaptogenix's regenerative therapeutics for neurodegeneration is based on extensive pre-clinical data demonstrating the induction of new, fully mature synaptic connections that restore cognitive function in models of Alzheimer's disease ("AD"), stroke, Fragile X syndrome, mental retardation and traumatic brain injury.

Synaptogenix to Present at Sachs 4th Annual Neuroscience Innovation Forum

NEW YORK, April 1, 2021 /PRNewswire/ -- Synaptogenix, Inc. (OTC: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced an update on its ongoing National Institute of Health ("NIH") sponsored Phase 2b clinical trial of Bryostatin-1 in patients suffering from moderately severe Alzheimer's disease ("AD"). To date, the Company has dosed 43 of its target 100 patients.

Synaptogenix Announces Phase 2b Bryostatin-1 Clinical Trial Update

NEW YORK, Feb. 25, 2021 /PRNewswire/ -- Synaptogenix, Inc. (OTC: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that it will attend two upcoming scientific industry conferences. On Thursday, February 25th, Dr....

Synaptogenix to Present at Upcoming Scientific Industry Conferences

NEW YORK, Feb. 12, 2021 /PRNewswire/ -- Synaptogenix, Inc. (OTC: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that Dr. Alan Tuchman M.D., Chief Executive Officer, and Dr. Daniel Alkon M.D., Chief Scientific...

Synaptogenix to Participate in the Winter Wonderland - Best Ideas from the Buy-Side Conference

NEW YORK, Jan. 21, 2021 /PRNewswire/ -- Synaptogenix, Inc. (the "Company" or Synaptogenix) (OTCQX: SNPX), formerly Neurotrope Bioscience, Inc., announced today that it has entered into definitive securities purchase agreements with accredited investors to raise approximately $14.0 million...

Synaptogenix Announces $14.0 Million Private Placement

News for Synaptogenix Stock (SNPX)